Study type

Study topic

Human medicinal product

Study type

Non-interventional study

Scope of the study

Drug utilisation
Safety study (incl. comparative)

Data collection methods

Secondary use of data
Non-interventional study

Non-interventional study design

Cohort
Study drug and medical condition

Name of medicine, other

Anti-inflammatory and antirheumatic products, non-steroids (NSAIDS) Defined by all M01A group except M01AX05, M01AX12, M01AX25 and M01AX26

Medical condition to be studied

Venous thrombosis
Population studied

Short description of the study population

Objective 1: Drug utilisation of NSAIDs.
The study population will be women aged 15-49 who initiate oral NSAIDs of ibuprofen, diclofenac and naproxen on or after 2014 while using hormonal contraceptives, defined using a 90-day washout window. We will require at least 365 days of data availability before NSAIDs use.
Objective 2 and 3: Incidence of VTE
The source population will be women of reproductive age using hormonal contraceptives or therapies. We will not limited to medication with contraceptive as indication, but also medications as a combination of estrogen and progestin for other indications. For example, the DIANE®-35, which contains ethinylestradiol and cyproterone acetate, is a treatment of moderate to severe acne related to androgen-sensitivity (with or without seborrhoea) and/or hirsutism in women of reproductive age, will be included in this study.
The study population will include women aged 15-49, using hormonal contraceptives, and with no history of venous or arterial thromboembolism, cancer (except non-melanoma skin cancer), thrombophilia, hysterectomy, bilateral oophorectomy, sterilisation or infertility treatment.

Age groups

Adults (18 to < 46 years)
Study design details

Study design

Drug/Vaccine Safety Studies
Patient-level DUS

Main study objective

1. To characterise the use of NSAIDs among women aged 15-49.
2. To measure the association of any NSAID use and the incidence of VTE among 15-49 years old women on high, medium, and low risk hormonal contraceptives.
3. To measure the association of ibuprofen, diclofenac and naproxen use on the incidence of VTE among 15-49 years old women on high, medium, and low risk hormonal contraceptives.